AllAnalyst Report
Morningstar•June 18, 2021
Morningstar•June 18, 2021DexCom, Inc.: With G7 Nearing Commercialization for Dexcom, We've Raised Our Fair Value Estimate
Summary
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CG
Upgrade to begin using premium research reports and get so much more.
Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level
UpgradeActions
Download Full ReportRelated Reports
- Analyst Report: Abbott LaboratoriesApr 23, 2024 •
ABT
- Market Update: ABT, ERIC, IVZApr 23, 2024 •
ABT, ERIC, IVZ
- The Argus Innovation Model PortfolioApr 23, 2024 •
GOOGL, AMAT, AAPL, ANET, CVX, ADI, AXON, URI, COST, V, LLY, SPGI, PANW, NVDA, META, SYK, BSX, ORCL, PWR, CBOE, MCK, NOW, LYFT, ADBE, SCHW, MCHP, ISRG, AMZN, CRM, ODFL
- Analyst Report: Atlassian CorporationApr 19, 2024 •
TEAM
- Analyst Report: Intuitive Surgical, Inc.Apr 19, 2024 •
ISRG
Analyst Profile
Debbie Wang
Senior Equity AnalystDebbie Wang is a senior equity analyst for Morningstar Research Services LLC, a wholly owned subsidiary of Morningstar, Inc. She covers the medical-device industry. Previously, she was an associate director of equity analysis for Morningstar, leading the healthcare team.Before joining Morningstar in 2002, Wang was a vice president and senior brand strategist for Leo Burnett. During her tenure at Leo Burnett, she led brand strategy on a variety of accounts, including Allstate, Amoco, McDonald/s, Heinz, Smucker’s, Pepto-Bismol, and Celebrex.Wang holds a bachelor’s degree in anthropology from Colgate University and a master’s degree in business administration from the University of Chicago Booth School of Business.